Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcellx Inc (ACLX)
NASDAQ:ACLX
Arcellx Inc (ACLX) Stock Price & Analysis
95 Followers
ACLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$30.74 - $75.10
Previous Close$51.65
Volume742.73K
Average Volume (3M)463.59K
Market Cap
$2.75B
Enterprise Value$2.15B
Total Cash (Recent Filing)$702.02M
Total Debt (Recent Filing)$97.63M
Price to Earnings (P/E)-34.1
Beta0.94
Next Earnings
May 08, 2024EPS Estimate
-$0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding52,796,618
10 Day Avg. Volume527,699
30 Day Avg. Volume463,591
Standard Deviation0.22
R-Squared0.00001
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)5.62
Price to Sales (P/S)43.18
Price to Cash Flow (P/CF)11.70
P/FCF Ratio12.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue19.47
Enterprise Value/Gross Profit19.47
Enterprise Value/Ebitda-36.61
Forecast
1Y Price Target
$79.70Price Target Upside54.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Arcellx Inc News
Bulls Say, Bears Say
Bulls Say
Company VisibilityArcellx Therapeutics' feature at the 23rd Annual Needham Healthcare Conference has enhanced the company's profile in the healthcare sector, signaling strong interest and confidence in its growth potential.
Manufacturing AdvancementsGilead's commitment to cutting CAR-T manufacturing time and achieving a high success rate positions anito-cel as a strong contender in the market with faster delivery times for patients.
Regulatory MilestoneThe FDA Advisory Committee's positive vote on using MRD as a surrogate endpoint could accelerate anito-cel's development timelines, offering a potential speedier path to market for this innovative therapy.
Bears Say
Clinical ConcernsFDA highlighted early deaths as a safety signal in CAR-T's use, pointing to a need for further investigation regarding the risk/benefit balance.
Manufacturing ChallengesLimited manufacturing supply remains the key issue for competitors CARVYKTI and ABECMA.
Survival DataQuestions have emerged regarding overall survival (OS) data for Abecma, with a hazard ratio (HR) of 1.01, which could impact the advisory committee's review.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $30.74 and its highest was $75.10 in the past 12 months.
What is Arcellx Inc’s market cap?
Currently, no data Available
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is May 08, 2024 which is in 15 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Feb 28, 2024. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of -$0.533 by $0.953.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Undervalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -$0.51.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 53,290,314 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of $0.42 in its last earnings report, beating expectations of -$0.533. Following the earnings report the stock price went down -2.228%.
Which hedge fund is a major shareholder of Arcellx Inc?
Among the largest hedge funds holding Arcellx Inc’s share is Perceptive Advisors LLC. It holds Arcellx Inc’s shares valued at 252M.
---
Arcellx Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.70 (54.31% Upside)
$79.70 (54.31% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 573.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $38.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.6%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.48%
12-Months-Change
Fundamentals
Return on Equity
-20.48%
Trailing 12-Months
Asset Growth
162.93%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
---
ACLX Stock 12 Months Forecast
Average Price Target
$79.70
▲(54.31% Upside)
Technical Analysis
Adverum Biotechnologies
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Meiragtx Holdings
―
Best Analysts Covering ACLX
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+87.15%
reiterated a buy rating 2 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +87.15% per trade.
---